This is a working overview of thymosin alpha-1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
=== Other uses === Use as an antitumor drug has also been proposed. Pentamidine is also identified as a potential small molecule antagonist that disrupts this interaction between S100P and RAGE receptor.
trace the evolution of a large number of organisms by measuring changes in their DNA, rather than through physical taxonomy or physiological observations alone, compare entire genomes, which permits the study of more complex evolutionary events, such as gene duplication, horizontal gene transfer, and the prediction of factors important in bacterial speciation, build complex computational population genetics models to predict the outcome of the system over time track and share information on an increasingly large number of species and organisms
=== Effect on French colonies === The Viet Minh victory in the war had an inspirational effect to independence movements in various French colonies worldwide, most notably the FLN in Algeria. The Algerian War broke out on 1 November 1954, only six months after the Geneva Conference. Benyoucef Benkhedda, later became the head of the Provisional Government of the Algerian Republic, praised the Viet Minh feat at Dien Bien Phu as "a powerful incentive to all who thought immediate insurrection the only possible strategy". The French Communist Party played an even stronger role by supplying the National Liberation Front (FLN) rebels with intelligence documents and financial aid. They were called "the suitcase carriers" (les porteurs de valises). In the French news, the Indochina War was presented as a direct continuation of the Korean War, where France had fought: a UN French battalion, incorporated in a U.S. unit in Korea, was later involved in the Battle of Mang Yang Pass of June and July 1954. In an interview taped in May 2004, General Marcel Bigeard (6th BPC) argues that "one of the deepest mistakes done by the French during the war was the propaganda telling you are fighting for Freedom, you are fighting against Communism", hence the sacrifice of volunteers during the climactic battle of Dien Bien Phu. In the latest days of the siege, 652 non-paratrooper soldiers from all army corps from cavalry to infantry to artillery dropped for the first and last time of their life to support their comrades.
Sources: en.wikipedia.org
==== Don Cossacks in World War II ==== In April 1936, the earlier ban on Cossacks serving in the Red Army was lifted. Later in 1936, two existing Red Army cavalry divisions were re-designated as Don Cossacks. In 1939, a number of these regiments were issued with traditional Cossack uniforms, in ceremonial and field service versions. The dress of the Don Cossack units included dark-blue breeches with broad red stripes which had distinguished them prior to the Revolution. The Don Cossack Cavalry Corps saw extensive active service until 1943, after which its role diminished, as did that of the other remaining horse-mounted units in the Red Army. However Don Cossack cavalry was still in existence in 1945 and participated in the Victory Parade in Moscow. During World War II, the Don Cossacks mustered the largest single concentration of Cossacks within the German Army, the XVth SS Cossack Cavalry Corps, a great part of them former Soviet citizens. The XVth SS Cossack Cavalry Corps included the 1st Cossack Division and the 2nd Cossack Division. The majority of the Cossacks remained loyal to the Red Army. In the earliest battles, particularly the encirclement of Belostok, Cossack units such as the 94th Beloglisnky, 152nd Rostovsky and 48th Belorechensky regiments fought to their death. In the opening phase of the war, during the German advance towards Moscow, Cossacks were extensively used for raids behind enemy lines.
== Clinical trials == Phase I clinical trials evaluated the safety, tolerability, and pharmacokinetics of canfosfamide. Phase II trials evaluated clinical activity in various tumor types, especially ovarian cancer and non-small cell lung cancer. Phase III trials focused on its efficacy as part of combination therapy, particularly with standard chemotherapeutic agents. However, the trials did not demonstrate significant improvement in overall survival when compared to standard treatments alone.
=== Targeted delivery vehicles === Specially targeted delivery vehicles aim to increase effective levels of chemotherapy for tumor cells while reducing effective levels for other cells. This should result in an increased tumor kill or reduced toxicity or both.
Sources: en.wikipedia.org
Strontium is a divalent silvery metal with a pale yellow tint whose properties are mostly intermediate between and similar to those of its group neighbors calcium and barium. It is softer than calcium and harder than barium. Its melting (777 °C) and boiling (1377 °C) points are lower than those of calcium (842 °C and 1484 °C respectively); barium continues this downward trend in the melting point (727 °C), but not in the boiling point (1900 °C). The density of strontium (2.64 g/cm3) is similarly intermediate between those of calcium (1.54 g/cm3) and barium (3.594 g/cm3). Three allotropes of metallic strontium exist, with transition points at 235 and 540 °C. The standard electrode potential for the Sr(2+)/Sr couple is −2.89 V, approximately midway between those of the Ca(2+)/Ca (−2.84 V) and Ba(2+)/Ba (−2.92 V) couples, and close to those of the neighboring alkali metals. Strontium is intermediate between calcium and barium in its reactivity toward water, with which it reacts on contact to produce strontium hydroxide and hydrogen gas. Strontium metal burns in air to produce both strontium oxide and strontium nitride, but since it does not react with nitrogen below 380 °C, at room temperature it forms only the oxide spontaneously. Besides the simple oxide SrO, the peroxide SrO2 can be made by direct oxidation of strontium metal under a high pressure of oxygen, and there is some evidence for a yellow superoxide Sr(O2)2. Strontium hydroxide, Sr(OH)2, is a strong base, though it is not as strong as the hydroxides of barium or the alkali metals.
=== 21st century === The chain peaked in 2008, having 601 restaurants in the US generating $2 billion in revenue. By 2023, sales had fallen to $728 million. In October 2009, Haymarket broke the world record for biggest profit made in any week, throughout TGI Fridays' history, and it has been home to several past winners from the bartenders Olympics, a contest started by Scoggin. On May 20, 2014, TGI Fridays was sold to Sentinel Capital Partners and TriArtisan Capital Partners. In October 2019, TriArtisan acquired Sentinel's stake in TGI Fridays. Allegro Merger began working towards taking Fridays public in 2019, buying it away from MFP Partners and TriArtisan Capital, but withdrawing in April 2020. Utz Quality Foods entered a marketing agreement with Inventure Foods in 2017 to use the "TGI Fridays" name for some of its snacks. In the UK, TGI Fridays re-branded to "Fridays", dropping the "TGI" prefix during 2020. About three years later, the naming reverted to "TGI Fridays".
== Careers in neuroscience == The career options for neuroscience graduates vary widely depending on the level of education. At the bachelor's level, graduates often enter laboratory research, healthcare support, biotechnology, or science communication, though some pursue broader fields such as policy or nonprofit work. With a master's degree, training may prepare individuals for applied health professions (e.g., occupational therapy, medicine -neurology, psychiatry, neuroimaging-, genetic counseling), research management, or public health. An advanced degree (PhD or equivalent) is usually required for independent research or university teaching.
In the presence of air and various cofactors and enzymes, fatty acids are converted to acetyl-CoA. The pathway is called beta-oxidation. Each cycle of beta-oxidation shortens the fatty acid chain by two carbon atoms and produces one equivalent each of acetyl-CoA, NADH, and FADH2. The acetyl-CoA is metabolized by the citric acid cycle to generate ATP, while the NADH and FADH2 are used by oxidative phosphorylation to generate ATP. Dozens of ATP equivalents are generated by the beta-oxidation of a single long acyl chain. In oxidative phosphorylation, the key control point is the reaction catalyzed by cytochrome c oxidase, which is regulated by the availability of its substrate – the reduced form of cytochrome c. The amount of reduced cytochrome c available is directly related to the amounts of other substrates: 1 2 NADH + cyt c ox + ADP + P i ⇌ 1 2 NAD + + cyt c red + ATP {\displaystyle {\frac {1}{2}}{\ce {NADH}}+{\ce {cyt}}\ {\ce {c_{ox}}}+{\ce {ADP}}+{\ce {P_{i}}}\rightleftharpoons {\frac {1}{2}}{\ce {NAD^+}}+{\ce {cyt}}\ {\ce {c_{red}}}+{\ce {ATP}}}
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.